case of seronegative immune-mediated necrotizing myopathy manifesting as dysphagia and transaminitis

Co-authors:
Folasade Arinze MD, MPH, FACP Internal medicine Wellstar Kennestone/ Marrietta, GA

We present a case of a 37-year-old man diagnosed with seronegative immune-mediated necrotizing myopathy (IMNM) after presenting with dysphagia, elevated creatine kinase, and transaminitis. Despite initial worsening, his condition significantly improved with high-dose IV methylprednisolone, confirming the diagnosis through a muscle biopsy and leading to a successful recovery with an oral prednisone taper.

References:
Asma Malik, G. H. (2016). Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Frontiers in Neurology.

Brittany L Adler, L. C.-S. (2018 ). Triggers of inflammatory myopathy: insights into pathogenesis. DIscovery medicine, 25(136): 75–83.

Chester V Oddis, R. A.-K. (2015). Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert review of clinical immunology, 1265-1275.

Gherardi, R. K. (2011). Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Medicale , 40(4 Pt 2):e209-18.

Gioia Merlonghi, G. A. (2022). Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge. Autoimmunity Reviews, 21(2), 102993.

Hunza Chaudhry, J. L. (2023). A tough pill to swallow: Two cases of statin-induced necrotizing autoimmune myopathy manifesting as dysphagia and transaminitis. SAGE Open Medical Case Reports.

Iago Pinal-Fernandez, C. P.-R.-S. (2016). Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis care and research.